Ara
Toplam kayıt 515, listelenen: 501-510
KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.
(Lippincott Williams & Wilkins, 2023)
...
Long-term course of COVID-19 vaccination-related headache: A prospective multicenter follow-up study
(SAGE Publications Ltd, 2023)
...
Real-life experiences with galcanezumab disclosed new predictors for response
(SAGE Publications Ltd, 2023)
...
Vascular comorbidity and cognition in migraine
(SAGE Publications Ltd, 2023)
...
Comparison of the effectiveness of the personalized schroth exercise and conventional therapy for scoliosis in children with rheumatic disease
(BMJ Publishing Group, 2023)
Background: Childhood rheumatic disease is one of the most common chronic diseases in childhood and adolescence [1]. In particular, it causes weakness, pain, problems in the musculoskeletal system, displacement of the ...
Idarubicin versus daunorubicin versus mitoxantrone for induction chemotherapy in acute myeloid leukemia: Patient registration study of Turkish society of hematologyacute myeloid leukemia working group
(American Society of Hematology, 2023)
Introduction: Standard induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) includes a combination of standard-dose cytarabine and an anthracycline (idarubicin [IDA], daunorubicin [DNR], or mitoxantrone ...
Acute myeloid leukemia in elderly, unfit patients: Analysis of Turkish AML prospective registry database, on behalf of acute leukemia working group of Turkish society of hematology
(American Society of Hematology, 2023)
Objective: Low dose Ara-C and hypomethylating agents (HMAs) - decitabine (DEC) and azacitidine (AZA) - have made it possible to treat more elderly patients with acute myeloid leukemia (AML). Both HMAs demonstrated efficacy ...
Open-label, randomized, phase 3 study of coformulated favezelimab and pembrolizumab versus chemotherapy in patients with relapsed or refractory classical hodgkin lymphoma refractory to anti-PD-1 therapy: Keyform-008
(American Society of Hematology, 2023)
Background: The importance of PD-1 therapy in relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) is well established, with PD-1 inhibitors such as pembrolizumab being a standard of care option for patients. ...